bicalutmide

Enzalutamide Prescribing Info Includes New Information

Enzalutamide (Xtandi) has a new, expanded FDA label. The new label conforms with the clinical trial (TERRAIN) results that Xtandi is a superior drug to Casodex (bicalutamide) for men with metastatic castration-resistant prostate cancer (CRPC). The updated product label shows enzalutamide reduces the risk of radiographic progression or death by 40% vs. bicalutamide. Median radiographic [...]

By Malecare|2017-10-19T10:46:01-04:00October 26th, 2016|Advanced Prostate Cancer, Casodex, enzalutamide, Uncategorized, Xtandi|0 Comments

Coming Back to Continue the Blog and New Data Disclosed on Enzalutamide at the Plenary Session at the 2015 European Association of Urology Congress

Before I get into the meat of today’s post about enzalutamide, I want to briefly make some personal comments about my absence from this blog. As I had mentioned I have been diagnosed with a fifth primary cancer, appendiceal cancer. It is a rare cancer, which required my having to remove my appendix, a piece [...]

By Malecare|2017-10-19T10:47:29-04:00March 24th, 2015|Advanced Prostate Cancer, Casodex, Clinical Trials, Clinical Trials, Drugs & Treatments, enzalutamide, Hormone Therapy, Uncategorized, Xtandi|0 Comments